DRY EYE DIAGNOSTICS
AXIM has developed and commercialized two FDA Cleared Diagnostic tests for Dye Eye Disease. The solutions are available now through exclusive partner Verséa Ophthalmic, LLC (“Verséa”), a subsidiary of Verséa Holdings, Inc.
COVID-19 & CANCER
AXIM Biotech has developed a rapid (10-minute) serological diagnostic test that detects SARS-CoV-2 neutralizing antibodies (Nabs) which are the antibodies needed to fight COVID-19 within the body. Additionally, using proprietary polyclonal antibodies in collaboration with world-renowned research and academic centers, AXIM has developed a prototype diagnostic test that measures levels of QSOX1-L in blood and filed for patent protection.
INNOVATIVE DIAGNOSTIC SOLUTIONS
AXIM works with clients around the world on development of diagnostic solutions of all kinds for a variety of conditions and indications. For more information, please contact AXIM.